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Chapter 1: Introduction
Breast cancer is uninhibited cellular growth that occurs within the breast. Although there
are many different forms of breast cancer, the most common type of breast cancer found in
women is ductal carcinoma in situ (DCIS). DCIS is a noninvasive form of breast cancer where
malignant cells arise and proliferate within the breast ducts without invasion of the basement
membrane. DCIS is a precursor for invasive ductal carcinoma and therefore if left untreated can
invade the epithelial membranes of the surrounding tissue and becomes an invasive infiltrating
type of breast cancer (Reynolds, 2013). Invasive ductal carcinoma may develop in 30 to 50% of
all DCIS cases (Lee, Vallow, McLaughlin, Hines, & Peterson, 2012).
Description and Prevalence of the Problem
One out of every eight women will be diagnosed with breast cancer. These statistics
make it the most frequently diagnosed cancer in women. The American Cancer Society projects
that 295,240 breast cancer diagnoses will occur in 2014, this includes invasive and noninvasive
breast cancer. The breast cancer mortality rate for 2014 is an estimated 13.6 % making it the
second leading cause of cancer death in women (American Cancer Society, n.d.). With statistics
such as these, it is not hard to comprehend why so much research is being done to find effective
treatments, preventative measures, or a cure for this disease.
Survival rates for breast cancer are determined by the cancer staging at diagnosis.
Research has show that an earlier diagnosis yields a better outcome. With the advancements in
screening technology and treatment, more women are being diagnosed early at a localized stage
and the average age range is 50 to 60. Most treatment regimens for breast cancer involve
surgery, chemotherapy, and radiation. These modalities are dictated by the National
Comprehensive Cancer Network (NCCN) guidelines. Given that these women are being
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diagnosed at a younger age, the treatments take weeks and months to complete. This places
these women with a hardship of treating their cancer while raising children, balancing a career,
and living life. Conventional radiation techniques that are the standard of care currently state
that women must have external beam radiation daily five days a week for an average of six
weeks.
Purpose Statement
The goal of this research is to assess the efficacy of single-fraction intra-operative
radiation therapy (IORT) using the Xoft Axxent System at time of breast conserving surgery for
early stage breast cancer. PICO: Intra-operative radiation therapy (IORT) using the Xoft Axxent
eBx System is no worse (non-inferior) that whole breast irradiation when used as stand-alone
radiation treatment in breast conserving therapy in women with early stage breast cancer.
Rationale for Review
The primary efficacy endpoint for this research is to demonstrate that the local recurrence
rate of intraoperative radiation therapy is non-inferior to external beam radiation. The potential
benefits of IORT are; elimination of tumor tissue, decrease the likelihood of recurrence, reduce
radiation delivered to non-target tissue, accelerated delivery system, reduced treatment time,
improved cosmetic aesthetics post treatment, and decrease the incident of skin fibrosis.
Definition of Major Terms
Breast Cancer- Cancer that forms in the tissue of the breast.
Breast Conservation Surgery- An operation to remove the breast cancer but not the breast itself.
Types of breast-conserving surgery include lumpectomy (removal of the lump), quadrantectomy
(removal of one quarter, or quadrant, of the breast), and segmental mastectomy (removal of the
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cancer as well as some of the breast tissue around the tumor and the lining over the chest muscles
below the tumor). Also called breast-sparing surgery (National Cancer Institute, n.d.).
Ductal Carcinoma in Situ- (DCIS) of the breast is characterized by malignant epithelia cells
confined to the ductal system of the breast without evidence of invasion through the basement
membrane into the surrounding tissue.
Intra-Operative Radiation Therapy- (IORT) is a single fractional dose of radiation that is
delivered directly to the tumor bed during breast conservation surgery.
Total Mastectomy- Surgery to remove the entire breast and surrounding lymph tissue.
Whole Breast Radiation Therapy (WBRT) or External Beam Radiation Therapy (EBRT)- Uses
high-energy x-ray (linear accelerator) to directly deliver radiation to the tumor.
Theoretical Framework
In researching the different treatment options available for breast cancer the theoretical
framework that seems to assess all aspects of the patient is Betty Neuman’s Systems Model.
Neuman’s System theory includes the following concepts; a wholistic client, an open system,
and stressors. The patient is viewed as a whole, whose body is in constant interaction with the
with the evolving environment, other people and within themselves (Neuman & Fawcett, 2002).
The interaction between any of these concepts can induce stress to the patient and disrupt
wholeness.
Stressors are viewed as anything that interrupts stability of an individual and posses a risk
to the body’s normal line of defense. The individual’s reaction to the stressor is dependent upon
the time of occurrence, the present and past condition of the individual and the individual’s
ability to adapt to the stressor. Stressors may be intra, inter, and extra-personal (Neuman&
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Fawcett, 2002). The stressors in regards to breast cancer and cancer treatment are discussed in
the following paragraphs.
Intrapersonal stressors are internal environmental forces occurring within the patient.
Examples of intrapersonal factors in relation to breast cancer that could pose stress to a client are
the initial diagnosis of cancer and the uncertainty of survival. The pain associated with surgical
removal of the cancer and any associated radiation treatments, alteration in body image and
disruption of the woman’s sexuality.
Interpersonal stressors are external environmental interaction forces occurring outside the
client (Neuman & Fawcett, 2002). Interpersonal stressors related to breast cancer may include
changes in role expectation within the family unit, or conflicts related to surgery, procedures and
treatments. Disruption to daily living by cancer treatment can cause the patient to have increased
stress and progress to requiring extra energy to adapt to this stressor.
Extrapersonal factors are external factors or interactions occurring outside of the patient
at a distant range, (Neuman & Fawcett, 2002). Hospitalization, frequent trips to the physician,
and radiation treatment are just a few examples of this type of stressor.
The ultimate goal of Neuman’s System Models in relation to breast cancer it to help the
patient deal with the interpersonal, intrapersonal, and extrapersonal stress factors. Positive
interaction with any of the stressor will help the patient cope with cancer and promote wellness
within, which will in turn return the person back to a whole.
Chapter 2: Literature Review
The literature search was accomplished using the CINAHL, Academic Search Premier,
and MEDLINE databases. Search words included “breast cancer,” “ductal carcinoma in situ,”
“Xoft,” and “intraoperative radiation therapy,” during the time period of 2004-2014. The
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inclusion criteria for this review were articles that focused on defining breast cancer and ductal
carcinoma in situ, and the modalities of treatment. All literature had to be scholarly and peer
reviewed. The reference lists of the selected articles were also reviewed and were included. The
literature is comprised of 1791 pertinent scholarly articles of breast cancer, types of breast cancer
and modalities of treatment.
Once considered to be a rare breast lesion, DCIS now constitutes 20 % of all newly
diagnosed breast cancer cases. One case of DCIS will be detected in every 1300 screening
mammograms (Siziopikou, 2013). Patients with DCIS can be asymptomatic at the time of
presentation (mammogram) or present with symptoms as a palpable mass or nipple discharge.
Prior to the advent of widespread screening mammograms DCIS was diagnosed by surgical
removal of a suspicious breast mass. The incidence of DCIS has markedly increased, primarily
due to improved screening and imaging techniques. This has led to a shift in disease
presentation from in the past where patients presented with symptomatology to the current period
where the disease is detected solely by abnormal mammographic finding (Moran et al., 2012).
Conventional mammography is the gold standard modality used for annual breast cancer
screening to detect calcifications as well as any soft tissue changes (Reynolds, 2013). On a
mammogram, DCIS appears as clustered microcalcifications. These calcifications differ in
density, form and size and are grouped together in linear or segmental arrangements reflecting
their presence in the ducts (Lee, Vallow, McLaughlin, Hines, & Peterson, 2012).
There are several risk factors associated with DCIS. Less educated women had a greater
cumulative incidence of DCIS than women with a higher education. Breast cancer registry data
consistently show that the incidence of DCIS increases until age 65-69 then declines. According
to the World Health Organization Collaborative Study on Neoplasia and Steroid Contraceptive
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there is a significant increase of DCIS in women over the age of 35 that used oral contraceptives.
Women with four or more children had a 38 % decreased risk of DCIS (Virnig, Shamliyan,
Tuttle, Kane, & Witt, 2009).
The management and treatment of DCIS is very controversial for many reasons. There
are no prospective randomized trails comparing mastectomy, breast conservation with radiation
and breast conservation without radiation for the treatment of DCIS. Retrospective data suggest
survival is similar among all methods of treatment (Lee, Vallow, McLaughlin, Hines, &
Peterson, 2012).
As the incidence of DCIS increases, the treatment options continue to evolve. Traditional
treatment for DCIS was total mastectomy, which often required cosmetic reconstruction surgery.
Previous standards of care have transitioned from radical surgery only (total mastectomy) to
bimodality treatments consisting of breast conservation surgery (BCS) partial mastectomy,
lumpectomy with external beam radiation treatment (EBRT) (Ash, Williams, Wagman, &
Forouzannia, 2013). The modality of treatment is based on type and stage of breast cancer the
patient has.
Mastectomy was traditionally the standard of care for DCIS and historical data
demonstrated the risk of local recurrence post mastectomy is extremely low. Simple mastectomy
remains a treatment option however results from the National Surgical Adjuvant Breast and
Bowel Program (NSABP) B17 study established that breast conservation surgery followed by
radiation as a standard treatment option for DCIS (Siziopikou, 2013).
Breast conservation surgery for DCIS combined with external beam radiation therapy can
reduce the risk of local recurrence but is associated with significant cost. Treatment modality of
using EBRT timespan ranges from five to seven weeks and is associated with interruption of
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daily life and financial burdens. Transportation to a radiation center, physical limitations and or
lack of family support may prevent many patients from selecting breast-conserving therapies. In
addition, EBRT is associated with potential acute and chronic toxicities to the surrounding
normal tissue such as dermatitis, soft tissue fibrosis, rib fractures, hyperpigmentation, and
volume loss of breast tissue in the treated breast and an increase risk of cardiac disease in
patients with left sided breast cancers (Ash, Williams, Wagman, & Forouzannia, 2013).
A therapeutic alternative to EBRT would be a treatment that has equivalent efficacy
while reducing overall toxicity and treatment duration. Intraoperative radiotherapy (IORT) is
radiotherapy that delivers radiation to the tumor bed during surgical excision of cancerous
lesions (Reitsamer et al., 2008). This treatment can reduce or eliminate the need for external
beam radiation therapy. This treatment approach has the potential to significantly reduce normal
tissue toxicity. IORT avoids radiation to the skin and limits radiation exposure to normal breast
tissue. Radiation dose to deep structures, such as heart, ribs and lungs is reduced since IORT
utilizes electron or low energy x-ray (Ash, Williams, Wagman, & Forouzannia, 2013). A highly
favorable aspect of IORT is direct visualization of the target volume need to ensure appropriate
treatment coverage needed and this visualization reduces the risk of geographic oversight (Sinha,
2008).
Ductal carcinoma in situ is a disease with heterogeneous clinical behaviors and successful
treatment of DCIS requires a multidisciplinary approach. At the present time no well-established
studies to direct the change of treatment or to predict the clinical behaviors of DCIS. Several
clinical trails such as Xoft and the TARGIT trail are ongoing and show many improved
strategies for treating breast cancer.
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Chapter 3: Methods
Design
This is a single-arm, historical controlled, non-randomized, non-inferiority study of
subjects treated with single fraction, intra-operative radiation therapy at the time of breast
conserving surgery for early stage breast cancer. This is a multicenter study being conducted at
The Sara Cannon Cancer Center at Parkridge Medical Center in Chattanooga Tennessee and
multiple centers across the United States, Spain and Germany. The Primary Investigator for the
Sarah Cannon Cancer Center is Dr. Stephen Golder a Radiation Oncologist and Sub Investigator
is Dr. Laura Witherspoon a specialty train breast surgeon.
This prospective study is sponsored and monitored by Xoft Axxent eBx Systems.
Subject that enrolled in this study will be only treated with the Xoft Axxent eBx System at the
time of breast conserving surgery.
Population
This phase IV clinical trail is currently enrolling up 1,600 to eligible participants in fifty
centers across the United States and Europe. The trial period will be ongoing during June 2012
to June 2014 and will be comprised of females greater than or equal to forty years of age.
Variables
The variables under study for this research are the following: age, sex, biopsy proven
invasive ductal carcinoma or ductal carcinoma in situ of ipsilateral or bilateral breast with tumors
less than or equal to 3.0 cm in greatest diameter. Cosmesis of bilateral breast using the Harvard
Scale and skin assessment is performed at baseline and during month 6,12, 18, year 2 and then
annually through 10 year follow up. The rate and severity of adverse events, disease free and
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overall all survival rates will be assessed during the ten-year follow up. Other variables assessed
were quality of life pre and post treatment. All these variables were compiled to evaluate the
success of intervention of Xoft intraoperative radiation therapy for breast cancer.
Measurements
The analysis of the primary endpoint of breast tumor recurrence at five and ten years will
be done by utilizing a random effects model for joint analysis of survival proportions reported at
multiple time points during the study. Patient baseline characteristics for age at enrollment,
ethnicity, menopausal status, tumor size, grade and classification, prior cancer history, family
history of breast cancer, pregnancy history, volume of tissue excise and medications will be
summarized. These comparisons are presented in order to identify any major baseline site or
therapy differences that could affects outcomes.
Descriptive statistics for continuous variables will consist of the mean, median, standard
deviation, minimum and maximum values. When comparisons are presented a Chi-Square test
for categorical variables, one-way ANOVA for continuous variables will be used or the
equivalent non-parametric test in the case where there is no identifiable distribution.
The Xoft Axxent Electronic Brachytherapy System and balloon applicator and sources
are FDA cleared. An independent Data and Safety Monitoring Board will review safety and
adverse events throughout the duration of the trial.
Results and Discussion
How Role Evolved
I first was made aware about this current research by speaking with Kassie Britton RN
who is the research coordination with the Sarah Cannon Cancer Center at Parkridge Medical
Center. I discussed with her my desire to get involved with some research project and she told
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me about some research projects going on within her department. This evolved as a beginning
point to be involved with the Xoft phase 4 clinical trials for early-staged breast cancer.
Role as Research Assistant
As a research assistant for this study I performed chart reviews on patients who were
diagnosed early stage breast cancer, ductal carcinoma in situ (DCIS) during a three-month period
of 2014. I audited and compiled the outcome variables of pre and postoperative visits. I
performed over 60 hours reading, interpreting, synthesizing and logging in data. I also assisted
the researcher in other ways such as organizing, storing, and filing paperwork for this study.
I was very fortunate to be able to follow one subject from the first interview for possible
participation to being involved during her surgical procedure and seeing first hand the
intraoperative radiation treatment. At her one month follow up I was able to assess her quality of
life post surgery and cosmeis of her breast post surgery and post IORT.
Findings
This study is still in the collection phase of its findings therefore no findings are available
to report at this time. The target enrollment date is completed and subject’s data will be followed
for a period of ten years.
Chapter 4: Evaluation
Overall I learned a great deal from this experience. This was my first experience with
research and synthesizing information from charts and interviewing subject for a study. I found I
gained more knowledge about breast cancer and cancer treatments. When I began my chart
reviews I found I had to look up a lot of information so I could understand what I was reading
from radiological reports, pathology reports and CT scans. Just simple terminology was hard to
interpret at first but the more I became familiar with anatomy of the breast and the various tools
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being used during the procedures I found I was quicker by the end. Overall this was a great
experience and it opened my eyes on how hard it is to conduct research and then to follow
through with the findings. This clinical trail has finished its enrollment period and subjects will
be followed during the next ten years and hopefully this research will aid in the advancement of
breast cancer treatment.

SAFETY AND EFFICACY OF XOFT

13
Reference

American Cancer Society. (n.d.). http://www.cancer.org
Ash, R. B., Williams, V. L., Wagman, L. D., & Forouzannia, A. (2013, February). Intraoperative
radiotherapy for breast cancer: its perceived simplicity. Oncology, 108-113. Retrieved
from www.cancernetwork.com
Lee, R. J., Vallow, L. A., McLaughlin, S. A., Hines, S. L., & Peterson, J. L. (2012). Ductal
carcinoma in situ of the breast. International Journal of Surgical Oncology, 2012.
http://dx.doi.org/10.1155/2012/123549
Moran, M. S., Bai, H. X., Hafty, B. G., Elenaor, E., Harris, R., Arthur, D. W., ... Bellon, J. R.
(2012, Jan-Feb). ACR appropriateness criteria ductal carcinoma in situ. Breast Journal,
18, 8-15. http://dx.doi.org/10.1111/j.1524-4741.2011.01197.x
National Cancer Institute. (n.d.). http://www.cancer.gov/
Neuman, B., & Fawcett, J. (2002). The neuman system model (4th ed.). Norwalk CT: Appleton
& Large.
Reitsamer, R., Sedimayer, F., Kopp, M., Kametriser, G., Menzel, C., Glueck, S., ... Peintinger, F.
(2008). Concepts and techniques of intraoperative radiotherapy for breast cancer. Breast
Cancer, 15, 40-46. http://dx.doi.org/10.1007/s12282-007-0001-4
Reynolds, A. (2013). Brest density and digital breast tomosynthesis. Radiologic Technology, 85,
63-82. Retrieved from http:/www.ncbi.nlm.nih.gov/pubmed/24029897
Sinha, A. (2008, Spring). Intraoperative radiation therapy. Radiation Therapist, 17, 17-29.
Retrieved from www.asrt.org/doc/publications-archive/ther_s08_combind.pdf
Siziopikou, K. P. (2013, April). Ductal carcinoma in situ of the breast. Archives of Pathology &
Laboratory Medicine, 137, 462-466. http://dx.doi.org/10.5858/arpa2012-0078-RA

SAFETY AND EFFICACY OF XOFT

14
Reference

Virnig, B. A., Shamliyan, T., Tuttle, T. M., Kane, R., & Witt, T. (2009). Diagnosis and
managemet of ductal carcinoma in situ (DCIS) [Executive Summary]. Retrieved from
Agency for Healthcare Research and Quality (US):
http://www.ncbi.nlm.nih.gov/books/NBK32568

SAFETY AND EFFICACY OF XOFT

15

